Menumenu
  • Home
  • Cardiovascular diseases Publications

Cardiovascular diseases Publications

Cardiovascular diseases Publications

  • Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.Abstract

    PURPOSE: After regulatory restrictions for terfenadine and astemizole in ’90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of indiidual antihistamines. METHODS: A matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project

    Poluzzi E, Diemberger I, DeRidder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, PilgaardUlrichsen S, Boriani G, Sturkenboom MCJ, DePonti F, Trifiro G. Eur J Clin Pharmacol. 2017 Aug 22; 1499 - 151.
  • Decrease in Switches to ‘Unsafe’ Proton Pump Inhibitors After Communications About Interactions with Clopidogrel.Abstract

    BACKGROUND: In 2009 and 2010 medicines regulatory agencies published official safety statements regarding the concomitant use of proton pump inhibitors and clopidogrel. We wanted to investigate a change in prescription behaviour in prevalent gastrorotective drug users (2008-2011). METHODS: Data on drug use were retrieved from the Out-patient Pharmacy Database of the PHARMO Database Network

    Kruik-Kolloffel WJ, van der Palen J, van Herk-Sukel MPP, Kruik HJ, Movig KLL. Clin Drug Investig. 2017 Aug; 37 787-794.
  • Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors.Abstract

    PURPOSE: To examine the associations between pharmaceutically treated anxiety and depression present in the year prior to breast cancer diagnosis and the risk of incident cardiovascular disease (CVD), while controlling for traditional cardiovascularisk factors and clinical characteristics in a population-based observational study

    Schoormans D, van dePoll-Franse L, Vissers P, van Herk-Sukel MPP, Peder sen SS, Rottmann N, Horsbol T, Dalton S, Denollet J. Breast Cancer Res Treat. 2017 Jul 17; 259-266.
  • Pre- and post-diagnostic beta-blocker use and lung cancer survival: A population-based cohort study.Abstract

    Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based on biased analyses. In this so far largest study we investigated the association betweeneta-blocker use and lung cancer survival. Therefore, patients with a lung cancer diagnosis between April 1998 and December 2011 were selected from a database linkage of the Netherlands Cancer Registry and the PHARMO Database Network

    Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel Mppv, Vissers PAJ, Brenner H. Sci Rep. 2017 Jun 06; 7 2911.
  • Use of azithromycin and risk of ventricular arrhythmia.Abstract

    BACKGROUND: There are conflicting findings from observational studies of the arrhythrogenic potential of azithromycin. Our aim was to quantify the association between azithromycin use and the risk of ventricular arrhythmia. METHODS: We conducted aested case-control study within a cohort of new antibiotic users identified from a network of 7 population-based health care databases in Denmark, Germany, Italy, the Netherlands and the United Kingdom for the period 1997-2010

    Trifiro G, deRidder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Molokhia M, Diemberger I, Sturkenboom Mcjm. CMAJ. 2017 Apr 18; 189 E560-E568.
  • Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period.Abstract

    AIMS: The aims of the present study were to assess antiplatelet drug use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet nonpersistence. METHODS: The present study was conducted in 4690 patients frm the Utrecht Cardiovascular Pharmacogenetics cohort with a first MI between 1986 and 2010, who were followed for a maximum of 10 years

    Yasmina A, de Boer A, Deneer VH, Souverein PC, Klungel OH. Br J Clin Pharmacol. 2017 Mar; 83 (3): 632-641.
  • Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands.Abstract

    PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged >/=18 years with an LDL-C meaurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemicstroke, peripheral arterial disease, and diabetes mellitus

    Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJ, Khan I, van Riemsdijk M, Herings RM. Clin Ther. 2017 Mar 24; 819 - 827.
  • Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands.Abstract

    OBJECTIVE: To describe clinical characteristics and cholesterol management of patients with cardiovascular events (CVEs) and/or type 2 diabetes mellitus (T2DM) with high low-density lipoprotein cholesterol (LDL-C) > 1.8 mmol/L in the Netherlands. RSEARCH DESIGN AND METHODS: From the PHARMO Database Network a cross-sectional cohort was constructed

    Heintjes E, Kuiper J, Lucius B, Penning-van Beest F, Kutikova L, Liem A, Herings R. Curr Med Res Opin. 2017 Jan; 33 (1): 91-100.
  • Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.Abstract

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blocers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts

    Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvan athan K, Cronin-Fenton D, DeSchutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Breast Cancer Res. 2016 Dec 01; 18 (1): 119.
  • Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study.Abstract

    OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents. METHODS: Children and adolescents (<19 yr) with1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort studybetween 1999 and 2009

    Ahmadizar F, FazeliFarsani S, Souverein PC, van der Vorst MM, deBoer A, Maitland-van der Zee AH. Pediatr Diabetes. 2016 Sep; 17 (6): 433-40.